APUS · Apimeds Pharmaceuticals US, Inc. · Debt
$1.85
+0.18 (+10.48%)
At close · Sep 18
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt about the Company's ability to continue as a going concern within one year after the date these condensed consolidated financial statements are issued.”View the 10-Q filed Aug 14, 2026
Market Cap
$2.47M
Shares
1.51M
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Debt data is being processed. Please check back later.